Company Snapshot: Paratek Pharmaceuticals

PRTK
Last	Change	Volume	High	Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

1. May 16 2022 Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
2. May 4 2022 Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
3. May 2 2022 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
4. Apr 26 2022 Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022